

Supplementary Table 1: Systemic Immunosuppressive Medications Prescribed to Subjects with Idiopathic Orbital Inflammatory Syndrome from 2013-2023

<u>Medication</u>	<u>% of Subjects (n, %)</u>
Corticosteroids	
Prednisone	923, 29.76%
Antimetabolites	
Methotrexate	408, 8.32%
Azathioprine	152, 2.99%
Mycophenolate	207, 4.10%
Calcineurin Inhibitors	
Tacrolimus	79, 1.55%
Oral cyclosporine	145, 2.88%
Alkylating Agents	
Cyclophosphamide	46, 0.89%
Chlorambucil	0, 0%
Biologics	
Adalimumab	112, 2.18%
Infliximab	49, 0.95%
Tocilizumab	30, 0.58%
Anakinra	10, 0.19%
Golimumab	10, 0.19%
Certolizumab pegol	11, 0.21%
Rituximab	209, 3.98%

Supplementary Table 2: Incidence of Ocular Complications in Idiopathic Orbital Inflammatory Syndrome Subjects

<u>Ocular Complication</u>	<u>Incidence (n, %)</u>
Diplopia	656, 12.86%
Proptosis	599, 11.74%
Low Vision and Blindness	506, 9.92%

Supplementary Table 3: Incidence of Systemic Inflammatory Diseases in Idiopathic Orbital Inflammatory Syndrome Subjects

<u>Disease</u>	<u>Incidence (n, %)</u>
Ankylosing Spondylitis	36, 0.71%
Rheumatoid Arthritis	395, 7.74%
Sarcoidosis	214, 4.19%
Sjogren Syndrome	207, 4.06%
Crohn's Disease	102, 2.00%
Ulcerative Colitis	90, 1.76%
Systemic Lupus Erythematosus	141, 2.76%
Behcet Disease	27, 0.53%
Scleroderma	22, 0.43%
Granulomatosis with Polyangiitis	14, 2.82%
Polymyositis	10, 0.20%
Relapsing Polychondritis	13, 0.25%
Microscopic Polyangiitis	13, 0.25%
Eosinophilic Granulomatosis with Polyangiitis	13, 0.25%